NodThera

NodThera

Edit info

  • Founded: 2016
  • Location: Lexington, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Peripheral and neuroinflammatory diseases
  • Drug types: NEU, IMM
  • Lead product: NT-0796
  • Funding: $55M B Jun 2020; £28M A Jun 2018


nodthera.com

linkedin.com

job board


Drug notes:

NT-0249 Clin1 inflammatory diseases; undisclosed RD/Clin0 neuroinflammatory diseases; undisclosed programs RD undisclosed

About:

NodThera is treating chronic diseases by targeting inflammation at its source. There is a growing volume of literature linking the NLRP3 inflammasome as the upstream catalyst of inflammation driving many chronic diseases of the body and brain. NodThera is identifying NLRP3-inhibitors by using novel chemistry, translatable assays and proprietary in-house in vivo models. These small molecules have several advantages over other therapies as they can potentially penetrate many tissue types and cross the blood brain barrier. In addition by targeting only NLRP3 inflammasomes, it spares other inflammasomes to fight infection.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com